Work

Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor– (ER) or androgen receptor (AR) –positive advanced breast carcinoma resistant to standard endocrine therapies.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.2525

Authors: B. Basu, J. E. Ang, D. Crawley, E. Folkerd, D. Sarker, M. Blanco-Codesido, K. Moran, S. Wan, N. Dobbs, F. Raynaud, S. R. D. Johnston, M. Dowsett, A. N. J. Tutt, J. F. Spicer, C. Swanton, J. S. De Bono

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2590633587

Cites:

Cited by: 8

Related to: 10